| Entry |
|
|---|
| Name |
Obinutuzumab (USAN);
Obinutuzumab (genetical recombination) (JAN);
Gazyva (TN)
|
|---|
| Product |
|
|---|
| Formula |
C6512H10060N1712O2020S44
|
|---|
| Exact mass |
145972.4812
|
|---|
| Mol weight |
146062.6732
|
|---|
| Remark |
| Therapeutic category: | 4291 |
|
|---|
| Efficacy |
Antineoplastic, Anti-CD20 antibody |
|---|
| Disease |
Chronic lymphocytic leukemia [DS: H00005] Follicular lymphoma [DS: H01613] |
|---|
| Comment |
Monoclonal antibody
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC15 Obinutuzumab
D09321 Obinutuzumab (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Obinutuzumab
D09321 Obinutuzumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D09321 Obinutuzumab (USAN); Obinutuzumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD20
D09321 Obinutuzumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09321
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09321
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09321
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09321
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D09321
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
